Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform

Raanana, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the submission of amended claims in its U.S. patent application for its proprietary intranasal drug delivery platform.